BBP news

Virtus LifeSci Biotech Products · Biotechnology · United States

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

24/7 Wall St. · 28 Oct 2026, 16:04 UTC
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
4.0% of BBP
wallstreet:online · 28 Oct 2026, 20:10 UTC
Ironwood Pharmaceuticals to Host Third Quarter 2026 Investor Update Call
1.6% of BBP
The Wall Street Journal · 28 Oct 2026, 20:17 UTC
Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff
1.5% of BBP
The Manila times · 28 Oct 2026, 23:09 UTC
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
1.4% of BBP
Where to buy BBP
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
TheStreet · 28 Oct 2026, 19:33 UTC
Breakthrough cancer vaccine catches Wall Street's attention
1.5% of BBP
Benzinga · 28 Oct 2026, 17:55 UTC
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth - Geron (NASDAQ:GERN)
1.5% of BBP
Where to buy BBP
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 28 Oct 2026, 17:33 UTC
Ligand Pharmaceuticals Q3 2026 Earnings Preview | Seeking Alpha
1.5% of BBP
Seeking Alpha · 28 Oct 2026, 20:02 UTC
Biogen anticipates $250M of run rate synergies by end of 2027 as it raises 2026 non-GAAP EPS to $12.20-$13 (NASDAQ:BIIB) | Seeking Alpha
1.4% of BBP
Seeking Alpha · 28 Oct 2026, 20:00 UTC
Biogen Inc. (BIIB) Q3 2026 Earnings Call Transcript | Seeking Alpha
1.4% of BBP
Seeking Alpha · 28 Oct 2026, 16:22 UTC
Moderna: ESMO Answered The Science, Q3 Has To Answer The Money (NASDAQ:MRNA) | Seeking Alpha
1.5% of BBP
Seeking Alpha · 28 Oct 2026, 19:01 UTC
Biogen Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:BIIB) 2026-10-28 | Seeking Alpha
1.4% of BBP
Seeking Alpha · 28 Oct 2026, 11:43 UTC
Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued (NASDAQ:REGN) | Seeking Alpha
1.7% of BBP
Investing.com · 28 Oct 2026, 15:42 UTC
Incyte earnings up next: Analysts eye loss amid pipeline gains By Investing.com
1.5% of BBP
Market Screener · 28 Oct 2026, 14:41 UTC
Adagene Inc. Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte?S Inca33890 in Patients with Microsatellite Stable Colorectal Cancer
1.5% of BBP
Investing.com · 28 Oct 2026, 14:13 UTC
Why is Moderna stock rebounding today? By Investing.com
1.5% of BBP
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
1.5% of BBP
Investing.com · 28 Oct 2026, 12:29 UTC
Why is Geron stock sliding today? By Investing.com
1.5% of BBP
Investing.com · 28 Oct 2026, 12:26 UTC
Geron stock tumbles after halting Phase 3 trial By Investing.com
1.5% of BBP
The Manila times · 28 Oct 2026, 12:13 UTC
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
1.5% of BBP
Seeking Alpha · 28 Oct 2026, 12:10 UTC
Fidelity Growth Company Fund Q3 2026 Commentary (FDGRX) | Seeking Alpha
1.5% of BBP

BBP news

Where to buy BBP

Where to buy BBP